Advertisement

Article | 2026 SARyV Meeting

HELIOS-3: Investigating Axpaxli for Diabetic Retinopathy

Peter K. Kaiser, MD, FASRS, discusses the phase 3 HELIOS-3 trial of AXPAXLI for diabetic retinopathy, which is enrolling patients in Argentina, the United States, and other countries.

By: Patricio G. Schlottmann, MD, Peter K. Kaiser, MD
Retinal Physician November 10, 2026
5 Key Takeaways

  • 1

    HELIOS-3 is a phase 3 trial evaluating AXPAXLI (OTX-TKI) for diabetic retinopathy and is enrolling patients in Argentina, the United States, and other countries.

  • 2

    Peter K. Kaiser said approved diabetic retinopathy treatments are generally used when patients have diabetic macular edema.

  • 3

    In earlier studies, patients who received one OTX-TKI injection were followed for 1 year, and all had stable or improved diabetic retinopathy.

  • 4

    In those earlier studies, 40% of sham-treated patients developed vision-threatening complications, compared with none of the patients who received OTX-TKI.

  • 5

    HELIOS-3 plans injections at baseline and week 48 and will compare OTX-TKI with sham for complications and changes in diabetic retinopathy.